ArticleJournal of hepatocellular carcinoma2026
CT-Based Radiomics for Non-Invasive Prediction of Ki-67 Expression in Hepatocellular Carcinoma.
Article in Journal of hepatocellular carcinoma, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Predictive Efficacy of a Combined Triphasic CT Radiomics and Clinical Feature Model for Ki-67 Expression in Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: By far, non-invasive methods assessing Ki-67 are still scarce. This study was performed to evaluate the capability of radiomics based on contrast-enhanced CT in predicting expression of Ki-67 in hepatocellular carcinoma (HCC). Patients and Methods: HCC patients who underwent curative hepatectomy were included. The optimal Ki-67 cutoff value for prognostic stratification was determined using maximum selection rank statistics. The Least Absolute Selection and Shrinkage Operator (LASSO) regression analysis was used for dimension reduction and data screening to obtain radiomics features. The radiomics model, clinical model and combined model integrating radiomics features and clinical indicators for predicting Ki-67 were constructed. The predictive efficacy among the models was compared using C-index, and further verified through DeLong test, decision curves and clinical impact curves. Results: The optimal cutoff value for Ki-67 was 0.25. A total of 2553 radiomics features were obtained and after stability testing (by intraclass correlation coefficient ≥0.75) and feature selection (LASSO), four radiomics features that were highly correlated and stable with the expression of Ki-67 were included in the model construction. Multivariate analyses revealed that alpha-fetoprotein and intratumoral necrosis or radiomics features were independent predictors of Ki-67. The clinical model, radiomics model and combined model were constructed, respectively. The C-indices of Ki-67 for clinical model, radiomics model and the combined model were 0.75, 0.82 and 0.88. DeLong test, decision curves and clinical impact curves further confirmed that the inclusion of radiomics features improved the predictive efficacy of the model. Conclusion: The comprehensive model based on contrast-enhanced CT radiomics could non-invasively and effectively predict the expression of Ki-67, suggesting its value in clinical decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.